LEADER 03778nam 2200841z- 450 001 9910557510503321 005 20210501 035 $a(CKB)5400000000044451 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/69449 035 $a(oapen)doab69449 035 $a(EXLCZ)995400000000044451 100 $a20202105d2020 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aVaccines against RNA Viruses 210 $aBasel, Switzerland$cMDPI - Multidisciplinary Digital Publishing Institute$d2020 215 $a1 online resource (166 p.) 311 08$a3-03943-623-6 311 08$a3-03943-624-4 330 $aRNA viruses cause animal, human, and zoonotic diseases that affect millions of individuals, as is being exemplified by the devastating ongoing epidemic of the recently identified SARS-Cov-2. For years vaccines have had an enormous impact on overcoming the global burden of diseases. Nowadays, a vast number of different approaches, from purified inactivated and live attenuated viruses, nucleic acid (DNA or RNA) based candidates, virus-like particles, subunit elements, and recombinant viruses are been employed to combat viruses. However, for many of them efficient vaccines are not yet available. This will probably change dramatically with the current Covid-19 pandemic, as a vast variety of vaccinology approaches are being tested against it, with hundreds of candidates under development, dozens of them already in clinical trials, a fact that is breaking records in vaccine development and implementation. This is becoming possible thanks to the enormous work carried out during years to have the bases for a quick response, even against unknown pathogens, in an impressive short time. Here, results obtained with different vaccine´s methodological approaches against human (HIV, HCV, HRV) animal (PRRSV, PEDV, FMDV, VHSV) and zoonotic (RVF, WNV), RNA viruses are presented by field experts. 606 $aMedicine$2bicssc 610 $aamount 610 $aanimal models 610 $aartificial protein 610 $abirds 610 $acellular response 610 $across protection 610 $aepitopes of broadly neutralizing HIV-1 antibodies 610 $aflavivirus 610 $aFMDV 610 $aGn Gc glycoproteins 610 $agnotobiotic pigs 610 $ahepatitis C virus 610 $aherd immunity 610 $aheterologous virus challenge 610 $aimmune pathways 610 $aimmune responses 610 $aimmunogenicity 610 $aintestine epithelial cells 610 $amodified vaccinia Ankara (MVA) 610 $aN gene 610 $an/a 610 $aneutralising antibodies 610 $aneutralizing antibodies 610 $anon-virion (NV) 610 $apassive serum:virus transfer 610 $apeptide mimic of discontinuous epitope 610 $apeptide vaccine 610 $apig 610 $apolyepitope B- and T-cell HIV-1 immunogen 610 $aporcine epidemic diarrhea virus 610 $aprocessivity factor 610 $aPRRS 610 $aPRRSV Mosaic T-cell DNA vaccine VACV 610 $arainbow trout 610 $aRift Valley fever virus (RVFV) 610 $aRNA interference 610 $arotavirus nanoparticle vaccine 610 $asingle dose 610 $atranscriptome profiling 610 $avaccines 610 $aVHSV 610 $aWest Nile virus 615 7$aMedicine 700 $aSaiz$b Juan Carlos$4edt$01310437 702 $aSaiz$b Juan Carlos$4oth 906 $aBOOK 912 $a9910557510503321 996 $aVaccines against RNA Viruses$93029816 997 $aUNINA